Our top pick for
BELLUS Health Inc is a biotechnology business based in the US. BELLUS Health shares (BLU) are listed on the NASDAQ and all prices are listed in US Dollars. BELLUS Health employs 17 staff and has a trailing 12-month revenue of around USD$17,269.
|Latest market close||USD$2.92|
|52-week range||USD$2.12 - USD$12.03|
|50-day moving average||USD$2.9412|
|200-day moving average||USD$3.5649|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.5084|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||-16.09%|
|1 month (2020-12-18)||2.92|
|3 months (2020-10-16)||22.18%|
|6 months (2020-07-17)||8.55%|
|1 year (2020-01-17)||-66.70%|
|2 years (2019-01-18)||273.74%|
|3 years (2018-01-17)||815.65%|
|5 years (2016-01-15)||305.56%|
|Gross profit TTM||USD$35,000|
|Return on assets TTM||-18.71%|
|Return on equity TTM||-32.11%|
|Market capitalisation||USD$239.6 million|
TTM: trailing 12 months
There are currently 777,153 BELLUS Health shares held short by investors – that's known as BELLUS Health's "short interest". This figure is 5% down from 817,943 last month.
There are a few different ways that this level of interest in shorting BELLUS Health shares can be evaluated.
BELLUS Health's "short interest ratio" (SIR) is the quantity of BELLUS Health shares currently shorted divided by the average quantity of BELLUS Health shares traded daily (recently around 1.3 million). BELLUS Health's SIR currently stands at 0.58. In other words for every 100,000 BELLUS Health shares traded daily on the market, roughly 580 shares are currently held short.
However BELLUS Health's short interest can also be evaluated against the total number of BELLUS Health shares, or, against the total number of tradable BELLUS Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BELLUS Health's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 BELLUS Health shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable BELLUS Health shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BELLUS Health.
Find out more about how you can short BELLUS Health stock.
We're not expecting BELLUS Health to pay a dividend over the next 12 months.
BELLUS Health's shares were split on a 277:1000 basis on 19 August 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 277 shares. This wouldn't directly have changed the overall worth of your BELLUS Health shares – just the quantity. However, indirectly, the new 261% higher share price could have impacted the market appetite for BELLUS Health shares which in turn could have impacted BELLUS Health's share price.
Over the last 12 months, BELLUS Health's shares have ranged in value from as little as $2.12 up to $12.03. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BELLUS Health's is -0.3691. This would suggest that BELLUS Health's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, BELLUS Health has bucked the trend.
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.